Clinical management of borderline ovarian tumors

Expert Review of Anticancer Therapy

Volumn 10, Issue 7, 2010, Pages 1115-1124

  Trillsch, F ^a   Mahner, S ^a   Ruetzel, J D ^a   Harter, P ^b   Ewald Riegler, N ^b   Jaenicke, F ^a   Du Bois, A ^b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b DR HORST SCHMIDT KLINIKEN   (Germany)

Author keywords

borderline ovarian tumor; clinical outcome; epidemiology; fertility; low malignant potential; mode of surgery; prognostic factor; recurrence

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE; CA 125 ANTIGEN; K RAS PROTEIN; PROTEIN C FOS;

AGE DISTRIBUTION; BORDERLINE OVARIAN TUMOR; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER INVASION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER STAGING; CONSERVATIVE TREATMENT; CYSTECTOMY; EPITHELIUM TUMOR; FEMALE FERTILITY; FROZEN SECTION; GYNECOLOGICAL EXAMINATION; HISTOLOGY; HISTOPATHOLOGY; HUMAN; HYSTERECTOMY; INTRAOPERATIVE PERIOD; LAPAROSCOPY; LAPAROTOMY; LYMPH NODE DISSECTION; LYMPHADENECTOMY; MALIGNANT TRANSFORMATION; MENTAL STRESS; OVARY CARCINOMA; OVARY TUMOR; POSTOPERATIVE CARE; PREMENOPAUSE; PROGNOSIS; REVIEW; SALPINGOOOPHORECTOMY; TRANSVAGINAL ECHOGRAPHY; ADULT; ALGORITHM; CARCINOMA; CELL DIVISION; CLINICAL TRIAL (TOPIC); DISEASE MANAGEMENT; FEMALE; INFERTILITY, FEMALE; MIDDLE AGED; MULTICENTER STUDY (TOPIC); MULTIMODALITY CANCER THERAPY; ONSET AGE; OVARIAN NEOPLASMS; OVARIECTOMY; PATHOLOGY; POSTOPERATIVE COMPLICATIONS; PROCEDURES; SURVIVAL; TUMOR INVASION; TUMOR RECURRENCE; YOUNG ADULT;

ADULT; AGE OF ONSET; ALGORITHMS; CARCINOMA; CELL DIVISION; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DISEASE MANAGEMENT; FEMALE; FROZEN SECTIONS; HUMANS; INFERTILITY, FEMALE; LAPAROSCOPY; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OVARIAN NEOPLASMS; OVARIECTOMY; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 77954870791     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.10.90     Document Type: Review

References (84)

1. Acs G. Serous and mucinous borderline (low malignant potential) tumors of the ovary. Am. J. Clin. Pathol. 123(Suppl.), S13-S57 (2005).
2. Taylor HC Jr. Malignant and semi- malignant tumors of the ovary. Surg. Gynecol. Obstet. 48, 204-230 (1929).
3. Tavassoli FA, Devilee P. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. IARC Press, Lyon, France (2003).
4. Lenhard MS, Mitterer S, Kumper C et al. Long-term follow-up after ovarian borderline tumor: relapse and survival in a large patient cohort. Eur. J. Obstet. Gynecol. Reprod. Biol. 145(2), 189-194 (2009).
5. Skirnisdottir I, Garmo H, Wilander E, Holmberg L. Borderline ovarian tumors in Sweden 1960-2005: trends in incidence and age at diagnosis compared to ovarian cancer. Int. J. Cancer 123(8), 1897-1901 (2008).
6. Tinelli R, Tinelli A, Tinelli FG, Cicinelli E, Malvasi A. Conservative surgery for borderline ovarian tumors: a review. Gynecol. Oncol. 100(1), 185-191 (2006).
7. Sherman ME, Berman J, Birrer MJ et al. Current challenges and opportunities for research on borderline ovarian tumors. Hum. Pathol. 35(8), 961-970 (2004).
8. Sherman ME, Mink PJ, Curtis R et al. Survival among women with borderline ovarian tumors and ovarian carcinoma: a population-based analysis. Cancer 100(5), 1045-1052 (2004).
9. Tempfer CB, Polterauer S, Bentz EK, Reinthaller A, Hefler LA. Accuracy of intraoperative frozen section analysis in borderline tumors of the ovary: a retrospective analysis of 96 cases and review of the literature. Gynecol. Oncol. 107(2), 248-252 (2007).
10. Hata K, Hata T, Manabe A, Kitao M. Ovarian tumors of low malignant potential: transvaginal Doppler ultrasound features. Gynecol. Oncol. 45(3), 259-264 (1992).
11. Coumbos A, Sehouli J, Chekerov R et al. Clinical management of borderline tumours of the ovary: results of a multicentre survey of 323 clinics in Germany. Br. J. Cancer 100(11), 1731-1738 (2009).
12. Cadron I, Leunen K, Van Gorp T, Amant F, Neven P, Vergote I. Management of borderline ovarian neoplasms. J. Clin. Oncol. 25(20), 2928-2937 (2007).
13. Baker P, Oliva E. A practical approach to intraoperative consultation in gynecological pathology. Int. J. Gynecol. Pathol. 27(3), 353-365 (2008).
14. du Bois A, Ewald-Riegler N, du Bois O, Harter P. Borderline tumors of the ovary - a systematic review [German]. Geburtsh Frauenheilk 69, 807-833 (2009).
15. Gershenson DM. Clinical management potential tumours of low malignancy. Best Pract. Res. Clin. Obstet. Gynaecol. 16(4), 513-527 (2002).
16. Heintz AP, Odicino F, Maisonneuve P et al. Carcinoma of the ovary. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. Int. J. Gynaecol. Obstet. 95(Suppl. 1), S161-S192 (2006).
17. Cadron I, Amant F, Van Gorp T, Neven P, Leunen K, Vergote I. The management of borderline tumours of the ovary. Curr. Opin. Oncol. 18(5), 488-493 (2006).
18. Bostwick DG, Tazelaar HD, Ballon SC, Hendrickson MR, Kempson RL. Ovarian epithelial tumors of borderline malignancy. A clinical and pathologic study of 109 cases. Cancer 58(9), 2052-2065 (1986).
19. Hart WR. Borderline epithelial tumors of the ovary. Mod. Pathol. 18(Suppl. 2), S33-S50 (2005).
20. Seidman JD, Soslow RA, Vang R et al. Borderline ovarian tumors: diverse contemporary viewpoints on terminology and diagnostic criteria with illustrative images. Hum. Pathol. 35(8), 918-933 (2004).
21. Bell DA, Weinstock MA, Scully RE. Peritoneal implants of ovarian serous borderline tumors. Histologic features and prognosis. Cancer 62(10), 2212-2222 (1988).
22. Bell KA, Smith Sehdev AE, Kurman RJ. Refined diagnostic criteria for implants associated with ovarian atypical proliferative serous tumors (borderline) and micropapillary serous carcinomas. Am. J. Surg. Pathol. 25(4), 419-432 (2001).
23. Seidman JD, Horkayne-Szakaly I, Haiba M, Boice CR, Kurman RJ, Ronnett BM. The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int. J. Gynecol. Pathol. 23(1), 41-44 (2004).
24. Stewart CJ, Brennan BA, Hammond IG, Leung YC, McCartney AJ, Ruba S. Intraoperative assessment of clear cell carcinoma of the ovary. Int. J. Gynecol. Pathol. 27(4), 475-482 (2008).
25. Ren J, Peng Z, Yang K. A clinicopathologic multivariate analysis affecting recurrence of borderline ovarian tumors. Gynecol. Oncol. 110(2), 162-167 (2008).
26. Burks RT, Sherman ME, Kurman RJ. Micropapillary serous carcinoma of the ovary. A distinctive low-grade carcinoma related to serous borderline tumors. Am. J. Surg. Pathol. 20(11), 1319-1330 (1996).
27. Silva EG, Gershenson DM, Malpica A, Deavers M. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent. Am. J. Surg. Pathol. 30(11), 1367-1371 (2006).
28. Prat J, De Nictolis M. Serous borderline tumors of the ovary: a long-term follow-up study of 137 cases, including 18 with a micropapillary pattern and 20 with microinvasion. Am. J. Surg. Pathol. 26(9), 1111-1128 (2002).
29. Chang SJ, Ryu HS, Chang KH, Yoo SC, Yoon JH. Prognostic significance of the micropapillary pattern in patients with serous borderline ovarian tumors. Acta Obstet. Gynecol. Scand. 87(4), 476-481 (2008).
30. Seidman JD, Kurman RJ. Ovarian serous borderline tumors: a critical review of the literature with emphasis on prognostic indicators. Hum. Pathol. 31(5), 539-557 (2000).
31. Kane A, Uzan C, Rey A et al. Prognostic factors in patients with ovarian serous low malignant potential (borderline) tumors with peritoneal implants. Oncologist 14(6), 591-600 (2009).
32. Silverberg SG, Bell DA, Kurman RJ et al. Borderline ovarian tumors: key points and workshop summary. Hum. Pathol. 35(8), 910-917 (2004).
33. Buttin BM, Herzog TJ, Powell MA, Rader JS, Mutch DG. Epithelial ovarian tumors of low malignant potential: the role of microinvasion. Obstet. Gynecol. 99(1), 11-17 (2002).
34. Longacre TA, McKenney JK, Tazelaar HD, Kempson RL, Hendrickson MR. Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long-term (or =5-year) follow-up. Am. J. Surg. Pathol. 29(6), 707-723 (2005).
35. Cusido M, Balaguero L, Hernandez G et al. Results of the national survey of borderline ovarian tumors in Spain. Gynecol. Oncol. 104(3), 617-622 (2007).
36. Smith Sehdev AE, Sehdev PS, Kurman RJ. Noninvasive and invasive micropapillary (low-grade) serous carcinoma of the ovary: a clinicopathologic analysis of 135 cases. Am. J. Surg. Pathol. 27(6), 725-736 (2003).
37. Palomba S, Zupi E, Russo T et al. Comparison of two fertility-sparing approaches for bilateral borderline ovarian tumours: a randomized controlled study. Hum. Reprod. 22(2), 578-585 (2007).
38. Morice P, Camatte S, Rey A et al. Prognostic factors for patients with advanced stage serous borderline tumours of the ovary. Ann. Oncol. 14(4), 592-598 (2003).
39. Kaern J, Trope CG, Kristensen GB, Abeler VM, Pettersen EO. DNA ploidy; the most important prognostic factor in patients with borderline tumors of the ovary. Int. J. Gynecol. Cancer 3(6), 349-358 (1993).
40. Yokoyama Y, Moriya T, Takano T et al. Clinical outcome and risk factors for recurrence in borderline ovarian tumours. Br. J. Cancer 94(11), 1586-1591 (2006).
41. Meyer JS, Gersell DJ, Yim S. Cell proliferation in ovarian carcinoma: superior accuracy of S-phase fraction (SPF) by DNA labeling index versus flow cytometric SPF, lack of independent prognostic power for SPF and DNA ploidy, and limited effect of SPF on tumor growth rate. Gynecol. Oncol. 81(3), 466-476 (2001).
42. Verbruggen MB, van Diest PJ, Baak JP, Broeckaert MA, Kenemans P, Verheijen RH. The prognostic and clinical value of morphometry and DNA cytometry in borderline ovarian tumors: a prospective study. Int. J. Gynecol. Pathol. 28(1), 35-40 (2009).
43. Benedet JL, Bender H, Jones H 3rd, Ngan HY, Pecorelli S. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int. J. Gynaecol. Obstet. 70(2), 209-262 (2000).
44. Kim JH, Kim TJ, Park YG et al. Clinical analysis of intra-operative frozen section proven borderline tumors of the ovary. J. Gynecol. Oncol. 20(3), 176-180 (2009).
45. Brun JL, Cortez A, Rouzier R et al. Factors influencing the use and accuracy of frozen section diagnosis of epithelial ovarian tumors. Am. J. Obstet. Gynecol. 199(3), 244 E241-E247 (2008).
46. Menzin AW, Gal D, Lovecchio JL. Contemporary surgical management of borderline ovarian tumors: a survey of the Society of Gynecologic Oncologists. Gynecol. Oncol. 78(1), 7-9 (2000).
47. Schmalfeldt B, Pfisterer J. Interdisziplindre S2k-Leitlinie fur die Diagnostik und Therapie malginer Ovarialtumoren. Verlag, Z (Ed.). Germany (2007).
48. Trope CG, Kristensen G, Makar A. Surgery for borderline tumor of the ovary. Semin. Surg. Oncol. 19(1), 69-75 (2000).
49. Fauvet R, Boccara J, Dufournet C, David-Montefiore E, Poncelet C, Darai E. Restaging surgery for women with borderline ovarian tumors: results of a French multicenter study. Cancer 100(6), 1145-1151 (2004). (Pubitemid 38325941)
50. Kurman RJ, Seidman JD, Shih IM. Serous borderline tumours of the ovary. Histopathology 47(3), 310-315 (2005).
51. McKenney JK, Balzer BL, Longacre TA. Lymph node involvement in ovarian serous tumors of low malignant potential (borderline tumors): pathology, prognosis, and proposed classification. Am. J. Surg. Pathol. 30(5), 614-624 (2006).
52. Fadare O. Recent developments on the significance and pathogenesis of lymph node involvement in ovarian serous tumors of low malignant potential (borderline tumors). Int. J. Gynecol. Cancer 19(1), 103-108 (2009).
53. Camatte S, Morice P, Thoury A et al. Impact of surgical staging in patients with macroscopic 'stage I' ovarian borderline tumours: analysis of a continuous series of 101 cases. Eur. J. Cancer 40(12), 1842-1849 (2004).
54. Desfeux P, Camatte S, Chatellier G, Blanc B, Querleu D, Lecuru F. Impact of surgical approach on the management of macroscopic early ovarian borderline tumors. Gynecol. Oncol. 98(3), 390-395
55. Morice P. Borderline tumours of the ovary and fertility. Eur. J. Cancer 42(2), 149-158 (2006).
56. Suh-Burgmann E. Long-term outcomes following conservative surgery for borderline tumor of the ovary: a large population-based study. Gynecol. Oncol. 103(3), 841-847 (2006).
57. Chan JK, Lin YG, Loizzi V, Ghobriel M, DiSaia PJ, Berman ML. Borderline ovarian tumors in reproductive-age women. Fertility-sparing surgery and outcome. J. Reprod. Med. 48(10), 756-760 (2003).
58. Morice P, Camatte S, El Hassan J, Pautier P, Duvillard P, Castaigne D. Clinical outcomes and fertility after conservative treatment of ovarian borderline tumors. Fertil. Steril. 75(1), 92-96 (2001).
59. Romagnolo C, Gadducci A, Sartori E, Zola P, Maggino T. Management of borderline ovarian tumors: results of an Italian multicenter study. Gynecol. Oncol. 101(2), 255-260 (2006).
60. Beiner ME, Gotlieb WH, Davidson B, Kopolovic J, Ben-Baruch G. Infertility treatment after conservative management of borderline ovarian tumors. Cancer 92(2), 320-325 (2001).
61. Seracchioli R, Venturoli S, Colombo FM, Govoni F, Missiroli S, Bagnoli A. Fertility and tumor recurrence rate after conservative laparoscopic management of young women with early-stage borderline ovarian tumors. Fertil. Steril. 76(5), 999-1004 (2001).
62. Yinon Y, Beiner ME, Gotlieb WH, Korach Y, Perri T, Ben-Baruch G. Clinical outcome of cystectomy compared with unilateral salpingo-oophorectomy as fertility-sparing treatment of borderline ovarian tumors. Fertil. Steril. 88(2), 479-484 (2007).
63. Marcickiewicz J, Brannstrom M. Fertility preserving surgical treatment of borderline ovarian tumour: long-term consequence for fertility and recurrence. Acta Obstet. Gynecol. Scand. 85(12), 1496-1500 (2006).
64. Poncelet C, Fauvet R, Boccara J, Darai E. Recurrence after cystectomy for borderline ovarian tumors: results of a French multicenter study. Ann. Surg. Oncol. 13(4), 565-571 (2006).
65. Salomon LJ, Lhomme C, Pautier P, Duvillard P, Morice P. Safety of simple cystectomy in patients with unilateral mucinous borderline tumors. Fertil. Steril. 85(5), 1510 e1511-e1514 (2006).
66. Zanetta G, Rota S, Lissoni A, Meni A, Brancatelli G, Buda A. Ultrasound, physical examination, and CA 125 measurement for the detection of recurrence after conservative surgery for early borderline ovarian tumors. Gynecol. Oncol. 81(1), 63-66 (2001).
67. Jung SE, Lee JM, Rha SE, Byun JY, Jung JI, Hahn ST. CT and MR imaging of ovarian tumors with emphasis on differential diagnosis. Radiographics 22(6), 1305-1325 (2002).
68. Fauvet R, Boccara J, Dufournet C, Poncelet C, Darai E. Laparoscopic management of borderline ovarian tumors: results of a French multicenter study. Ann. Oncol. 16(3), 403-410 (2005). (Pubitemid 40458316)
69. Odegaard E, Staff AC, Langebrekke A, Engh V, Onsrud M. Surgery of borderline tumors of the ovary: retrospective comparison of short-term outcome after laparoscopy or laparotomy. Acta Obstet. Gynecol. Scand. 86(5), 620-626 (2007).
70. Deffieux X, Morice P, Camatte S, Fourchotte V, Duvillard P, Castaigne D. Results after laparoscopic management of serous borderline tumor of the ovary with peritoneal implants. Gynecol. Oncol. 97(1), 84-89 (2005).
71. De Iaco P, Ferrero A, Rosati F et al. Behaviour of ovarian tumors of low malignant potential treated with conservative surgery. Eur. J. Surg. Oncol. 35(6), 643-648 (2009).
72. Trope C, Kaern J, Vergote IB, Kristensen G, Abeler V. Are borderline tumors of the ovary overtreated both surgically and systemically? A review of four prospective randomized trials including 253 patients with borderline tumors. Gynecol. Oncol. 51(2), 236-243 (1993).
73. Sieben NL, Roemen GM, Oosting J, Fleuren GJ, van Engeland M, Prat J. Clonal analysis favours a monoclonal origin for serous borderline tumours with peritoneal implants. J. Pathol. 210(4), 405-411 (2006).
74. Ayhan A, Guvendag Guven ES, Guven S, Kucukali T. Recurrence and prognostic factors in borderline ovarian tumors. Gynecol. Oncol. 98(3), 439-445 (2005).
75. Mantzavinos T, Kanakas N, Genatas C, Papadias K, Zourlas PA. Five years' follow-up in two patients with borderline tumours of the ovary hyperstimulated by gonadotrophin therapy for in-vitro fertilization. Hum. Reprod. 9(11), 2032-2033 (1994).
76. Ortiz BH, Ailawadi M, Colitti C et al. Second primary or recurrence? Comparative patterns ofp53 and K-ras mutations suggest that serous borderline ovarian tumors and subsequent serous carcinomas are unrelated tumors. Cancer Res. 61(19), 7264-7267 (2001).
77. Parker RL, Clement PB, Chercover DJ, Sornarajah T, Gilks CB. Early recurrence of ovarian serous borderline tumor as high-grade carcinoma: a report of two cases. Int. J. Gynecol. Pathol. 23(3), 265-272 (2004).
78. Kurman RJ, Shih Ie M. Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int. J. Gynecol. Pathol. 27(2), 151-160 (2008).
79. Levanon K, Crum C, Drapkin R. New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J. Clin. Oncol. 26(32), 5284-5293 (2008).
80. Kurman RJ, Visvanathan K, Roden R, Wu TC, Shih Ie M. Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis. Am. J. Obstet. Gynecol. 198(4), 351-356 (2008).
81. Meinhold-Heerlein I, Bauerschlag D, Hilpert F et al. Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential. Oncogene 24(6), 1053-1065 (2005).
82. Bonome T, Lee JY, Park DC et al. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res. 65(22), 10602-10612 (2005).
83. Mahner S, Baasch C, Schwarz J et al. C-Fos expression is a molecular predictor of progression and survival in epithelial ovarian carcinoma. Br. J. Cancer 99(8), 1269-1275 (2008).
84. Plaxe SC. Epidemiology of low-grade serous ovarian cancer. Am. J. Obstet. Gynecol 198(4), 459 E451-E458 (2008). 74